If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-09. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Sclerosis (from Ancient Greek σκληρός (sklērós) 'hard') is the stiffening of a tissue or anatomical feature, usually caused by a replacement of the normal organ-specific tissue with connective tissue. The structure may be said to have undergone sclerotic changes or display sclerotic lesions, which refers to the process of sclerosis. Common medical conditions whose pathology involves sclerosis include:
, to determine various relationships between transmittance and concentration, and absorbance and concentration. Because a spectrophotometer measures the wavelength of a compound through its color, a dye-binding substance can be added so that it can undergo a color change and be measured. It is possible to know the concentrations of a two-component mixture using the absorption spectra of the standard solutions of each component. To do this, it is necessary to know the extinction coefficient of this mixture at two wavelengths and the extinction coefficients of solutions that contain the known weights of the two components. In addition to the traditional Beer-Lamberts law model, cuvette based label free spectroscopy can be used, which add an optical filter in the pathways of the light, enabling the spectrophotometer to quantify concentration, size and refractive index of samples following the hands law. Spectrophotometers have been developed and improved over decades and have been widely used among chemists. Additionally, spectrophotometers are specialized to measure either UV or Visible light wavelength absorbance values. It is considered to be a highly accurate instrument that is also very sensitive and therefore extremely precise, especially in determining color change. This method is also convenient for use in laboratory experiments because it is an inexpensive and relatively simple process.
=== Perrault method === This approach, discovered by Perrault and Chan in 2009, uses hydroquinone to reduce HAuCl4 in an aqueous solution that contains 15 nm gold nanoparticle seeds. This seed-based method of synthesis is similar to that used in photographic film development, in which silver grains within the film grow through addition of reduced silver onto their surface. Likewise, gold nanoparticles can act in conjunction with hydroquinone to catalyze reduction of ionic gold onto their surface. The presence of a stabilizer such as citrate results in controlled deposition of gold atoms onto the particles, and growth. Typically, the nanoparticle seeds are produced using the citrate method. The hydroquinone method complements that of Frens, as it extends the range of monodispersed spherical particle sizes that can be produced. Whereas the Frens method is ideal for particles of 12–20 nm, the hydroquinone method can produce particles of at least 30–300 nm.
=== 1947–1948 === In January 1947, the AHE was renamed the "Arab Higher Committee", with Amin al-Husayni as its chairman and Jamal al-Husayni as vice-chairman, and expanded to include the four remaining core members plus Hasan Abu Sa'ud, Izhak Darwish al-Husayni, Izzat Darwaza, Rafiq al-Tamimi and Mu'in al-Madi. This restructuring of the AHC to include additional supporters of Amin al-Husayni was seen as a bid to increase his political power. Following the failure of the London Conference, the British referred the question to the UN on 14 February 1947. In April 1947, the Arab Higher Committee repeated Arab and Palestinian demands in the solution for the Question of Palestine:
Sources: en.wikipedia.org
==== Phospholipases ==== Phospholipase is an enzyme that transforms the phospholipid molecule into a lysophospholipid (soap) → the new molecule attracts and binds fat and ruptures cell membranes. Phospholipase A2 is one specific type of phospholipases found in snake venom. Snake example: Okinawan habu (Trimeresurus flavoviridis)
Saffron likely originated in Iran, Greece, Mesopotamia, or Kashmir. Harold McGee states that it was domesticated in or near Greece during the Bronze Age. C. sativus is probably a triploid form of Crocus cartwrightianus, which is also known as "wild saffron". Saffron crocus was slowly propagated by humans throughout much of Eurasia and was later brought to parts of North Africa, North America, and Oceania. Several wild species of Crocus similar to the commercial plant are known to have been harvested in recent times for use as saffron. Crocus ancyrensis was used to make saffron in Sivas in Central Turkey, the corms were also eaten. Crocus cartwrightianus was harvested on Andros in the islands of the Cyclades, for medicinal purposes and the stigmas for making a pigment called Zafran. Crocus longiflorus stigmas were used for saffron in Sicily. Crocus thomasii stigmas were used to flavour dishes around Taranto, South Italy. In Syria the stigmas of an unknown wild species were collected by women and children, sun-dried and pressed into small tablets which were sold in the Bazaars. Not all ancient depictions or descriptions of saffron spice or flowers are certain to be the same species as the modern commercial species used for spice.
== Discography == OutKast - Speakerboxx/The Love Below Co-wrote "Church" & "Bust" Performed on "I Like The Way You Move" "Church", "Bust", "Unhappy", "Ghetto Musick", "Happy Valentine"s Day", "Bowtie" and "War" Outkast - Idlewild Wrote & Performed "Mutron Angel" Co-Wrote & Performed on "The Train" Co-Wrote & Performed on "A Bad Note" Joi - Tennessee Slim Is The Bomb Performed on "Co Stars" Outkast - Aquemini Co-wrote "Liberation" Performed on various tracks Khujo Goodie - The Man Not The Dawg Produced, co-wrote & performed on "Pimpz & Hoz" & "Shawtly" Pink - "Can"t Take Me Home" Performed on "You Make Me Sick" re-mix Raphael Saadiq - Live at the House Of Blues Performed on all tracks Big Gipp - Mutant Mindframe Performed on "Creeks" Killa Mike - Monster Performed on "A.D.I.D.A.S." and Monster Joi - Amoeba Cleansing Syndrome Performed on "U Turn Me On" OutKast - Big Boi & Dre Present Outkast Greatest Hits Performed on "The Whole World" OutKast - Atliens Co-wrote "You May Die" Performed on various tracks Goodie Mob - Still Standing Produced & co-wrote "Just About Over", performed on "Just About Over" & "They Don't Dance No Mo", "I Feel Responsible" and "The Walk" Soundtrack - Scooby Doo Original Movie Soundtrack Performed on "Land Of A Million Drums" Backbone - "Concrete Law" Performed on "Yes Yes Ya"ll", "Believe That" and "Under Streetlights" Soundtrack - Tomb Raider Original Movie Soundtrack Performed on "Speed Ballin" Soundtrack - Ali Original Movie Soundtrack Performed on "Set Me Free" & "Death Letter" Dungeon Family - Even In Darkness Performed on "Follow The Light" and "Rollin" Slimm Calhoun - "The Skinny" Performed on "Dirt Work", "Current Events" and "Red Clay" OutKast - Stankonia Performed on various tracks Witch Doctor - Witch Doctor Performed on "Goo Goo Eyes" Lil Will - Wrote, co-produced, & performed on "I Still Love You", performed on "Georgia Girl" Soundtrack - Shaft Performed on "Automatic" TLC - Fanmail Performed on "Silly Ho" Cool Breeze - East Points Greatest Hits Co-wrote "Ghetto Camelot" Performed on "Ghetto Camelot", "Creatine", "East Pointed" and "The Field" Soundtrack - Light It Up Original Movie Soundtrack Performed on "High Schoolin" Macy Gray - Macy Gray On How Life Is Performed on "Git Up, Git Out, Git Something"
== Anti-Xa Peptides == In addition to Draculin, several other naturally occurring anti-Xa polypeptides function as physiological serine-protease inhibitors, including Antistasin from the leech Haementeria officinalis, the tick anticoagulant peptide (TAP) from Ornithodoros moubata, Ecotin from E. coli, and the anticoagulant peptide AcAP. These peptides act as reversible slow, tight-binding inhibitors; however, Antistasin and Ecotin are cleaved by FXa while TAP remains unaffected by the protease. Draculin's noncompetitive inhibition prevents cleavage by the protease FXa, enabling the toxin to preserve anticoagulation and prevent clot formation while the bat feeds and digests. Compared to the other anti-Xa polypeptides, such as Antistasin, Ecotin, rTAP, and AcAP, Draculin has significant larger kinetic parameters of Ki=13.76-14.80 x 10-9 M (Kd), Kon=1.117 x 106 (M-1 s -1), and Koff=15.833 x 10-3(s-1). Draculin's significant larger Koff supports the conclusion of Draculin being a weaker inhibitor.
=== Pituitary adenoma === About 98% of cases of acromegaly are due to the overproduction of growth hormone by a benign tumor of the pituitary gland called an adenoma. These tumors produce excessive growth hormone and compress surrounding brain tissues as they grow larger. In some cases, they may compress the optic nerves. Expansion of the tumor may cause headaches and visual disturbances. In addition, compression of the surrounding normal pituitary tissue can alter the production of other hormones, leading to changes in menstruation and breast discharge in women and impotence in men because of reduced testosterone production. A marked variation in rates of GH production and the aggressiveness of the tumor occurs. Some adenomas grow slowly and symptoms of GH excess are often not noticed for many years. Other adenomas grow rapidly and invade surrounding brain areas or the sinuses, which are located near the pituitary. In general, younger people tend to have more aggressive tumors. Most pituitary tumors arise spontaneously and are not genetically inherited. Many pituitary tumors arise from a genetic alteration in a single pituitary cell that leads to increased cell division and tumor formation. This genetic change, or mutation, is not present at birth but is acquired during life. The mutation occurs in a gene that regulates the transmission of chemical signals within pituitary cells; it permanently switches on the signal that tells the cell to divide and secrete growth hormones.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.